BJH - volume 6, issue Abstract Book BHS, january 2015
D. Selleslag MD, C. Lambert MD, P. Zachée MD, PhD, D. Dierickx MD, PhD
BJH - 2014, issue Abstract Book BSTH, november 2014
A. Boban , C. Lambert MD, C. Hermans MD, PhD
BJH - 2014, issue Abstract Book BSTH, november 2014
S. Paulus , A. Boban , C. Lambert MD, C. Hermans MD, PhD
BJH - volume 5, issue Abstract Book BHS, january 2014
A. De Cuyper , R. Galot , A. Ferrant , D. Latinne , L. Knoops MD, PhD, L. Michaux MD, PhD, V. Havelange MD, PhD, M-C. Vekemans MD, C. Lambert MD, E. Van den Neste MD, PhD, X. Poiré MD, PhD
BJH - volume 4, issue 1, march 2013
A. Janssens MD, PhD, C. Lambert MD, G. Bries MD, PhD, A. Bosly MD, PhD, D. Selleslag MD, Y. Beguin MD, PhD
The Belgian Hematological Society (BHS) guideline panel on adult primary immune thrombocytopenia (ITP) reviewed the recent literature on diagnosis and treatment to make recommendations on the best strategies for frontline and subsequent-line treatment. No treatment is necessary for patients with platelet counts higher than 30000/μl in the absence of bleeding symptoms. Patients newly diagnosed or relapsing after a long-term treatment-free period can be managed with corticosteroids with or without intravenous immunoglobulins. A second line therapy is indicated for those patients who are intolerant or unresponsive to or relapse after initial corticosteroid treatment and have a risk of bleeding. The guideline panel recommends splenectomy as it is the treatment with the highest curative potential and an acceptable safety profile. If possible, splenectomy should be delayed to at least twelve months after diagnosis as spontaneous remission can occur in this time period. Thrombopoietin receptor (TPO-R) agonists are recommended for patients who are refractory to or relapse after splenectomy or who have a contra-indication to splenectomy irrespective of the duration of ITP. The guideline panel agrees that rituximab, azathioprine, cyclophosphamide, cyclosporine A, danazol, dapsone, mycophenolate mofetil and vincristine/vinblastine are potential treatment options, especially for patients refractory to TPO-R agonists.
(BELG J HEMATOL 2013;1:11–20)
Read moreBJH - 2013, issue BHS Abstractbook, january 2013
F. Van Obbergh MD, C. Lambert MD, O. Ciccarelli , C. Dangoisse , C. Sempoux , L. Knoops MD, PhD, A. Ferrant , L. Michaux MD, PhD, M-C. Vekemans MD
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
